SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020HIV Pipeline - Kirsten WhiteView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020First Day Treatment, Definition - Dr Paul SaxView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Clinical Relevance of Diagnostic Testing - Carlo Federico PernoView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Clinical Aspects - Prof Milosz ParczewskiView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Cancer, archived resistance mutations - Romain PalichView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2020Charles Flexner - Patients with Poor or Good AdherenceView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseCentral and Eastern European Meeting on Viral Hepatitis and HIV 2020Gilleece, Yvonne - The Management of Hepatitis in PregnancyView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseCentral and Eastern European Meeting on Viral Hepatitis and HIV 2020Long-Acting Therapies: Which Patients Will Benefit Most? - Dr. Sharon WalmsleyView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseCentral and Eastern European Meeting on Viral Hepatitis and HIV 2020Debate: Do Integrase Inhibitors and/or TAF Lead to Weight Gain? Con Standpoint - Jürgen RockstrohView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseCentral and Eastern European Meeting on Viral Hepatitis and HIV 2020PrEP Implementation in the CEE Region: What are the Successes, What are the Barriers? Prof. Milosz ParczewskiView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseCOVID-19Central and Eastern European Meeting on Viral Hepatitis and HIV 2020HIV and COVID-19 co-infection: An update Cristiana OpreaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseCentral and Eastern European Meeting on Viral Hepatitis and HIV 20202020: Have We Reached the 90-90-90 Targets? - Teymur NooriView Slideset
